Allergies News and Research

Latest Allergies News and Research

Federal funding for partnership to combat infectious diseases

Oregon Health & Science University and the University of Washington, along with a number of partner institutions across the Northwest, have received federal funding to form a regional research center aimed at combating emerging or re-emerging infectious diseases that pose a serious threat to human health.

15 Apr 2009

Stressed pregnant women more likely to have asthmatic children

Pregnant women who are stressed, particularly late in pregnancy, have an increased risk of their child going on to develop asthma, according to the latest research from Children of the 90s.

15 Apr 2009

Safety of Bitter orange herbal weight loss product questioned

The Australian Therapeutic Goods Administration (TGA) is reportedly examining whether there are any risks associated with an over-the-counter (OTC) herbal weight loss programme sold in Australia.

13 Apr 2009

FDA stops Neilgen Pharmaceuticals and Advent Pharmaceuticals from making unapproved drugs

The U.S. Food and Drug Administration today announced that it had obtained a permanent injunction barring Neilgen Pharmaceuticals Inc. of Westminster, Md., its parent company, Advent Pharmaceuticals, Inc. (Advent), of East Windsor, N.J., and two of their officers, Bharat Patel and Pragna Patel, from manufacturing and distributing any unapproved, adulterated or misbranded drugs.

12 Apr 2009

Treatment for acid reflux does not improve asthma symptoms

A commonly used treatment for acid reflux does not improve asthma symptoms or control in patients who do not have symptoms of gastroesophageal reflux (GER), according to a new study supported by the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health and by the American Lung Association (ALA).

12 Apr 2009

Mylan settles Clarinex patent case

Mylan Inc. has announced the settlement of all patent litigation relating to Desloratadine Tablets, 5 mg, the generic version of Schering- Plough's Clarinex allergy medication.

9 Apr 2009

Homeopathy in dogs pilot indicates need for larger clinical trial

Results from a small, rigorously designed, research study at the University of Bristol's Department of Clinical Veterinary Science have pointed the way towards a larger clinical trial of homeopathy for the treatment of atopic dermatitis in dogs.

7 Apr 2009

Discovery of gene variant associated with increased risk of atopic dermatitis

Scientists of the Max Delbrück Center for Molecular Medicine (MDC) Berlin-Buch and Charité - University Medical School, Berlin, Germany, in collaboration with researchers from the Klinikum rechts der Isar of Technical University Munich and Christian Albrecht University, Kiel, have identified a gene variant on chromosome 11 that is associated with an increased risk of atopic dermatitis.

6 Apr 2009

Niacin findings could open up new avenues for drug discovery

Deft molecular detective work at Duke University Medical Center suggests that scientists may soon be able to resurrect niacin as one of the best and cheapest ways to manage cholesterol.

6 Apr 2009

Researchers find an increased rate of unintentional injection of epinephrine from auto-injectors for anaphylaxis

Researchers find an increased rate of unintentional injection of epinephrine from auto-injectors for anaphylaxis (severe allergic reactions) and urge people who may need to administer the life-saving drug to themselves or others in an allergic emergency to receive regular coaching in its proper use.

6 Apr 2009

Allergies may be caused by a malfunction of the respiratory epithelium

One reason for the development of allergy may be malfunction of the respiratory epithelium, which allows allergens to bind to, enter and travel through the epithelium.

6 Apr 2009

Locking parasites in host cell could be new way to fight malaria

Researchers at the University of Pennsylvania have discovered that parasites hijack host-cell proteins to ensure their survival and proliferation, suggesting new ways to control the diseases they cause.

6 Apr 2009

Aerovance starts phase IIb clinical trial with Aerovant for uncontrolled asthma

Aerovance Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial, of inhaled dry powder Aerovant in patients with uncontrolled asthma.

2 Apr 2009

Targeted approach to kill specific disease-causing bacteria in the mouth

Research to develop a narrow-spectrum antibiotic that can target a particular species of bacteria without harming the other "good" bacteria present was described at the Society for General Microbiology meeting at Harrogate today (Thursday April 2).

1 Apr 2009

Explanation for poor infant immune response to certain vaccines

For years, researchers and physicians have known that infants' immune systems do not respond well to certain vaccines, thus the need for additional boosters as children develop.

1 Apr 2009

New HIV drug may help patients not responding to treatment

A potential treatment for HIV may one day help people who are not responding to Anti-Retroviral Therapy, suggests new research published tomorrow in The Journal of Immunology.

1 Apr 2009

Ultrasound saves money, improves rheumatologic care

A few years back, 76-year-old Joseph Buggie woke up to pain so throbbing, he couldn't muster the strength to roll over, let alone crawl out of bed.

31 Mar 2009

Discovery of new role for certain lung cells in the immune response to airborne allergens

Researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and at Ghent University in Ghent, Belgium, have identified a new role for certain lung cells in the immune response to airborne allergens.

30 Mar 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

Mylan's Matrix receives tentative FDA approval under PEPFAR for generic Truvada

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.2% controlling interest, has received the first tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its Abbreviated New Drug Application (ANDA) for Emtricitabine and Tenofovir Disoproxil Fumarate Tablets, 200 mg/300 mg.

30 Mar 2009